938 related articles for article (PubMed ID: 31171000)
1. High IL2RA mRNA expression is an independent adverse prognostic biomarker in core binding factor and intermediate-risk acute myeloid leukemia.
Du W; He J; Zhou W; Shu S; Li J; Liu W; Deng Y; Lu C; Lin S; Ma Y; He Y; Zheng J; Zhu J; Bai L; Li X; Yao J; Hu D; Gu S; Li H; Guo A; Huang S; Feng X; Hu D
J Transl Med; 2019 Jun; 17(1):191. PubMed ID: 31171000
[TBL] [Abstract][Full Text] [Related]
2. Gene expression of BAALC, CDKN1B, ERG, and MN1 adds independent prognostic information to cytogenetics and molecular mutations in adult acute myeloid leukemia.
Haferlach C; Kern W; Schindela S; Kohlmann A; Alpermann T; Schnittger S; Haferlach T
Genes Chromosomes Cancer; 2012 Mar; 51(3):257-65. PubMed ID: 22072540
[TBL] [Abstract][Full Text] [Related]
3. CD34 expression predicts an adverse outcome in patients with NPM1-positive acute myeloid leukemia.
Dang H; Chen Y; Kamel-Reid S; Brandwein J; Chang H
Hum Pathol; 2013 Oct; 44(10):2038-46. PubMed ID: 23701943
[TBL] [Abstract][Full Text] [Related]
4. Risk stratification of intermediate-risk acute myeloid leukemia: integrative analysis of a multitude of gene mutation and gene expression markers.
Rockova V; Abbas S; Wouters BJ; Erpelinck CA; Beverloo HB; Delwel R; van Putten WL; Löwenberg B; Valk PJ
Blood; 2011 Jul; 118(4):1069-76. PubMed ID: 21596848
[TBL] [Abstract][Full Text] [Related]
5. ERG expression is an independent prognostic factor and allows refined risk stratification in cytogenetically normal acute myeloid leukemia: a comprehensive analysis of ERG, MN1, and BAALC transcript levels using oligonucleotide microarrays.
Metzeler KH; Dufour A; Benthaus T; Hummel M; Sauerland MC; Heinecke A; Berdel WE; Büchner T; Wörmann B; Mansmann U; Braess J; Spiekermann K; Hiddemann W; Buske C; Bohlander SK
J Clin Oncol; 2009 Oct; 27(30):5031-8. PubMed ID: 19752345
[TBL] [Abstract][Full Text] [Related]
6. Risk assessment in patients with acute myeloid leukemia and a normal karyotype.
Bienz M; Ludwig M; Leibundgut EO; Mueller BU; Ratschiller D; Solenthaler M; Fey MF; Pabst T
Clin Cancer Res; 2005 Feb; 11(4):1416-24. PubMed ID: 15746041
[TBL] [Abstract][Full Text] [Related]
7. Integrative prognostic risk score in acute myeloid leukemia with normal karyotype.
Damm F; Heuser M; Morgan M; Wagner K; Görlich K; Grosshennig A; Hamwi I; Thol F; Surdziel E; Fiedler W; Lübbert M; Kanz L; Reuter C; Heil G; Delwel R; Löwenberg B; Valk PJ; Krauter J; Ganser A
Blood; 2011 Apr; 117(17):4561-8. PubMed ID: 21372155
[TBL] [Abstract][Full Text] [Related]
8. Presence of FLT3-ITD and high BAALC expression are independent prognostic markers in childhood acute myeloid leukemia.
Staffas A; Kanduri M; Hovland R; Rosenquist R; Ommen HB; Abrahamsson J; Forestier E; Jahnukainen K; Jónsson ÓG; Zeller B; Palle J; Lönnerholm G; Hasle H; Palmqvist L; Ehrencrona H;
Blood; 2011 Nov; 118(22):5905-13. PubMed ID: 21967978
[TBL] [Abstract][Full Text] [Related]
9. High expression levels of the ETS-related gene, ERG, predict adverse outcome and improve molecular risk-based classification of cytogenetically normal acute myeloid leukemia: a Cancer and Leukemia Group B Study.
Marcucci G; Maharry K; Whitman SP; Vukosavljevic T; Paschka P; Langer C; Mrózek K; Baldus CD; Carroll AJ; Powell BL; Kolitz JE; Larson RA; Bloomfield CD;
J Clin Oncol; 2007 Aug; 25(22):3337-43. PubMed ID: 17577018
[TBL] [Abstract][Full Text] [Related]
10. Single nucleotide polymorphism in the mutational hotspot of WT1 predicts a favorable outcome in patients with cytogenetically normal acute myeloid leukemia.
Damm F; Heuser M; Morgan M; Yun H; Grosshennig A; Göhring G; Schlegelberger B; Döhner K; Ottmann O; Lübbert M; Heit W; Kanz L; Schlimok G; Raghavachar A; Fiedler W; Kirchner H; Döhner H; Heil G; Ganser A; Krauter J
J Clin Oncol; 2010 Feb; 28(4):578-85. PubMed ID: 20038731
[TBL] [Abstract][Full Text] [Related]
11. Prognostic significance of combined BAALC and MN1 gene expression level in acute myeloid leukemia with normal karyotype.
Marjanovic I; Karan-Djurasevic T; Kostic T; Virijevic M; Vukovic NS; Pavlovic S; Tosic N
Int J Lab Hematol; 2021 Jun; 43(3):433-440. PubMed ID: 33242229
[TBL] [Abstract][Full Text] [Related]
12. Expression of CD4 is correlated with an unfavorable prognosis in wild-type NPM1, FLT3-ITD-negative cytogenetically normal adult acute myeloid leukemia.
Guo RJ; Atenafu EG; Schimmer AD; Minden MD; Chang H
Int J Lab Hematol; 2017 Aug; 39(4):429-437. PubMed ID: 28318150
[TBL] [Abstract][Full Text] [Related]
13. CD25 expression status improves prognostic risk classification in AML independent of established biomarkers: ECOG phase 3 trial, E1900.
Gönen M; Sun Z; Figueroa ME; Patel JP; Abdel-Wahab O; Racevskis J; Ketterling RP; Fernandez H; Rowe JM; Tallman MS; Melnick A; Levine RL; Paietta E
Blood; 2012 Sep; 120(11):2297-306. PubMed ID: 22855599
[TBL] [Abstract][Full Text] [Related]
14. Incidences and Prognostic Impact of c-KIT, WT1, CEBPA, and CBL Mutations, and Mutations Associated With Epigenetic Modification in Core Binding Factor Acute Myeloid Leukemia: A Multicenter Study in a Korean Population.
Park SH; Lee HJ; Kim IS; Kang JE; Lee EY; Kim HJ; Kim YK; Won JH; Bang SM; Kim H; Song MK; Chung JS; Shin HJ
Ann Lab Med; 2015 May; 35(3):288-97. PubMed ID: 25932436
[TBL] [Abstract][Full Text] [Related]
15. Incidence and prognostic influence of DNMT3A mutations in acute myeloid leukemia.
Thol F; Damm F; Lüdeking A; Winschel C; Wagner K; Morgan M; Yun H; Göhring G; Schlegelberger B; Hoelzer D; Lübbert M; Kanz L; Fiedler W; Kirchner H; Heil G; Krauter J; Ganser A; Heuser M
J Clin Oncol; 2011 Jul; 29(21):2889-96. PubMed ID: 21670448
[TBL] [Abstract][Full Text] [Related]
16. Prognostic significance of CEBPA mutations and BAALC expression in acute myeloid leukemia Egyptian patients with normal karyotype.
El-Sharnouby JA; Ahmed LM; Taha AM; Kamal O
Egypt J Immunol; 2008; 15(1):131-43. PubMed ID: 20306678
[TBL] [Abstract][Full Text] [Related]
17. Prognostic importance of histone methyltransferase MLL5 expression in acute myeloid leukemia.
Damm F; Oberacker T; Thol F; Surdziel E; Wagner K; Chaturvedi A; Morgan M; Bomm K; Göhring G; Lübbert M; Kanz L; Fiedler W; Schlegelberger B; Heil G; Schlenk RF; Döhner K; Döhner H; Krauter J; Ganser A; Heuser M
J Clin Oncol; 2011 Feb; 29(6):682-9. PubMed ID: 21205756
[TBL] [Abstract][Full Text] [Related]
18. Wilms Tumor 1 Expression at Diagnosis Correlates With Genetic Abnormalities and Polymorphism But Is Not Independently Prognostic in Acute Myelogenous Leukemia: A Hokkaido Leukemia Net Study.
Hidaka D; Onozawa M; Hashiguchi J; Miyashita N; Kasahara K; Fujisawa S; Hayase E; Okada K; Shiratori S; Goto H; Sugita J; Nakagawa M; Hashimoto D; Kahata K; Endo T; Yamamoto S; Tsutsumi Y; Haseyama Y; Nagashima T; Mori A; Ota S; Sakai H; Ishihara T; Imai K; Miyagishima T; Kakinoki Y; Kurosawa M; Kobayashi H; Iwasaki H; Shimizu C; Kondo T; Teshima T
Clin Lymphoma Myeloma Leuk; 2018 Nov; 18(11):e469-e479. PubMed ID: 30082223
[TBL] [Abstract][Full Text] [Related]
19. High EVI1 Expression Predicts Poor Outcomes in Adult Acute Myeloid Leukemia Patients with Intermediate Cytogenetic Risk Receiving Chemotherapy.
Qin YZ; Zhao T; Zhu HH; Wang J; Jia JS; Lai YY; Zhao XS; Shi HX; Liu YR; Jiang H; Huang XJ; Jiang Q
Med Sci Monit; 2018 Feb; 24():758-767. PubMed ID: 29408852
[TBL] [Abstract][Full Text] [Related]
20. BCRP mRNA and FLT3-ITD are independent poor risk factors in adult patients with acute myeloid leukemia and intermediate or normal karyotype.
Nasiłowska-Adamska B; Warzocha K; Solarska I; Borg K; Pieńkowska-Grela B; Czyż A
Eur J Haematol; 2017 Sep; 99(3):255-261. PubMed ID: 28618074
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
